Navigation Links
Results of the STACCATO Trial reported at TCT 2011
Date:11/10/2011

SAN FRANCISCO, CA NOVEMBER 10, 2011 Researchers leading a clinical trial said that transapical transcatheter aortic valve implantation (a-TAVI) may be inferior to surgical aortic valve replacement (SAVR) in operable elderly patients. However results were only preliminary as the trial was carried out on 70 patients out of a planned 200 before it was terminated early for safety concerns. Results from the STACCATO trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

TAVI has become a treatment option for patients with aortic valve stenosis, who are not amenable or at high risk to SAVR. The goal of the STACCATO trial was to compare a-TAVI with SAVR in operable elderly patients.

Researchers planned a 1:1 randomization of 200 unselected operable AVS patients with no need for revascularization and aged ≥ 75 years. The primary endpoint was the composite of death, stroke and/or renal failure at 30 days. Two Danish university centers participated after more than 40 TAVI procedures had been performed with good results at each center.

After inclusion of 70 patients (34 apical TAVI, 36 SAVR), the study was terminated after advice from the Data Safety Monitoring Board, because of an excess of events in the apical TAVI group. Baseline characteristics were similar in the two groups. The primary endpoint was met in five TAVI patients (two deaths, two major strokes, and one case of renal failure) compared to one stroke in the SAVR group.

"In its present phase of development, transapical transcatheter aortic valve implantation may be inferior to surgical aortic valve replacement in operable elderly patients," said Leif Thuesen, MD, the lead investigator of the trial. Dr. Thuesen is from the Department of Cardiology at Aarhus University Hospital in Denmark.

Researchers noted that after study termination, these procedures have been optimized by routine preoperative multi-slice computed tomography (MSCT) assessment and by the availability of the 29 mm valve. Further improvement is likely to take place with improved devices and pre-procedure assessment, they said.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the DEB-AMI Trial reported at TCT 2011
2. Results of the RIFLE STEACS clinical trial reported at TCT 2011
3. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
4. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
5. Combination epigenetic therapy clinical trial results
6. Results of the PARIS registry Reported at TCT 2011
7. Results of the TRIGGER-PCI trial reported at TCT 2011
8. Results of rapid gene trial reported at TCT 2011
9. Results of the BRIDGE trial reported at TCT 2011
10. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
11. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: